PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Cash & equivalents declining -10.40% while CRVO's grows 16.69%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Cash + STI yoy 1.25-1.5x CRVO's -9.45%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of CRVO's 1518.88%. David Dodd sees a leaner approach to short-term items.
-10.80%
Similar yoy growth to CRVO's -10.45%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-9.91%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Higher Other Non-Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-8.44%
Both CRVO and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Similar yoy to CRVO's -10.45%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Less than half of CRVO's -100.00%. David Dodd sees fewer expansions in other current obligations.
-12.74%
Less than half of CRVO's -52.04%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Less than half of CRVO's 1.64%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
0.5-0.75x CRVO's -6.92%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
≥ 1.5x CRVO's -11.65%. David Dodd sees stronger capital base growth than competitor.
-10.73%
Similar yoy to CRVO's -10.45%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
10.43%
Less than half of CRVO's -16.69%. David Dodd sees better deleveraging or stronger cash buildup than competitor.